1
|
Traore B, Kassogue Y, Diakite B, Diarra F, Cisse K, Kassogue O, Diarra M, Coulibaly A, Coulibaly B, Diallo H, Diarra Z, Ly M, Maiga A, Sissoko SB, Sissoko AS, Traore CB, Kamate B, Teguete I, Bah S, Dolo G, Gursel DB, Holl J, Hou L, Maiga M. Prevalence of high-risk human papillomavirus genotypes in outpatient Malian women living with HIV: a pilot study. BMC Infect Dis 2024; 24:513. [PMID: 38778266 PMCID: PMC11110247 DOI: 10.1186/s12879-024-09412-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 05/17/2024] [Indexed: 05/25/2024] Open
Abstract
INTRODUCTION Long-term exposure to high-risk human papillomavirus (Hr-HPV) is a well-known necessary condition for development of cervical cancer. The aim of this study is to screen for Hr-HPV using vaginal self-sampling, which is a more effective approach to improve women's adherence and increase screening rates. METHODS This pilot study included a total of 100 Women living with HIV (WLWHIV), recruited from the Center for Listening, Care, Animation, and Counseling of People Living with HIV in Bamako. Hr-HPV genotyping was performed on Self-collected samples using the Cepheid GeneXpert instrument. RESULTS The median age of WLWHIV was 44 (interquartile range [IQR], 37-50) years. Approximately 92% of the study participants preferred self-sampling at the clinic, and 90% opted to receive result notifications via mobile phone contact. The overall prevalence of Hr-HPV among study participants was 42.6%, and the most frequent Hr-HPV sub-types observed were HPV18/45 (19.1%), HPV31/35/33/52/58 (13.8%), and HPV39/68/56/66 (12.8%), followed by HPV16 (5.3%), and HPV51/59 (5.3%). WLWHIV under 35 years of age had a higher frequency of Hr-HPV compared to their older counterparts, with rates of 30% versus 11.1% (p = 0.03). The duration of antiretroviral treatment showed an inverse association with Hr-HPV negativity, with patients on treatment for 15 (IQR, 10-18) years versus 12 (IQR = 7-14) years for Hr-HPV positive patients (95% CI [1.2-5.8], t = 3.04, p = 0.003). WLWHIV with baseline CD4 T-Cell counts below 200 exhibited a higher frequency of Hr-HPV compared to those with baseline CD4 T-Cell counts above 200 (17.9% versus 1.9%, p = 0.009). However, other demographics and clinical factors, such as marital status, age of sexual debut, parity, education, history of abortion, history of preeclampsia, and cesarean delivery, did not influence the distribution of Hr-HPV genotypes. CONCLUSION Our findings indicate that WLWHIV under the age of 35 years old exhibited the highest prevalence of Hr-HPV infection, with HPV18/45 being the most prevalent subtype. Additionally, WLWHIV with baseline CD4 T-Cell counts below 200 showed the highest infection rates.
Collapse
Affiliation(s)
- Ban Traore
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Sciences and Techniques, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Yaya Kassogue
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali.
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
| | - Brehima Diakite
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Fousseyni Diarra
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
| | - Kadidiatou Cisse
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
| | - Oumar Kassogue
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
| | - Modibo Diarra
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
| | - Aissata Coulibaly
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
| | - Bourama Coulibaly
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Hama Diallo
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Zoumana Diarra
- Center of Listening, Care, Animation, and Counseling for People Living With HIV, Bamako, Mali
| | - Madani Ly
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
| | - Aminata Maiga
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Sidi Boula Sissoko
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Adama Seydou Sissoko
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Cheick Bougadari Traore
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Bakarou Kamate
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Ibrahima Teguete
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Sekou Bah
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Guimogo Dolo
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
| | - Demirkan Besim Gursel
- Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | - Jane Holl
- Department of Neurology, University of Chicago, Chicago, IL, 60637, USA
| | - Lifang Hou
- Institute for Global Health, Northwestern University, Chicago, IL, 60611, USA
- Preventive Medicine Department, Northwestern University, Chicago, IL, 60611, USA
| | - Mamoudou Maiga
- Centre of Research and Training on Molecular Pathologies, University Hospital of Point G, Bamako, Mali
- Faculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali
- Preventive Medicine Department, Northwestern University, Chicago, IL, 60611, USA
| |
Collapse
|
2
|
Kumthekar P, Grimm SA, Aleman RT, Chamberlain MC, Schiff D, Wen PY, Iwamoto FM, Gursel DB, Reardon DA, Purow B, Kocherginski M, Helenowski I, Raizer JJ. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv 2022; 4:vdac123. [PMID: 36225651 PMCID: PMC9549880 DOI: 10.1093/noajnl/vdac123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Systemic therapies for refractory meningiomas are limited with no FDA-approved therapeutics. Vascular endothelial growth factor (VEGF) is a signaling protein associated with neovascularization, peritumoral edema, and meningioma tumorigenesis. Methods This phase II study investigates the efficacy of bevacizumab (BEV), a VEGF binding monoclonal antibody, in patients with progressive Grade I (G1M), Grade II (G2M), Grade III (G3M) meningioma, and other non-parenchymal tumors including vestibular schwannoma (n = 4) and hemangiopericytoma (n = 4) with the primary endpoint of progression-free survival rate at 6-months (PFS-6). Non-meningiomas were included with the respective meningioma grade in the analysis. Secondary endpoints include median overall survival (mOS) and response rate. Results Fifty Patients (26 women; median age 54 years; range 23-81), 42 with progressive meningioma were treated: 10 G1M, 20 G2M, and 12 G3M. Prior treatments include surgical resection (41 patients), radiosurgery (24 patients), external beam radiotherapy (28 patients), and chemotherapy (14 patients). Median infusions administered were 16 (range, 2-68). Response was graded using the Macdonald's criteria. PFS-6, median PFS, and mOS were 87%, 22 months, 35 months for G1M; 77%, 23 months, 41 months for G2M; and 46%, 8 months, 12 months for G3M. Best radiographic responses include stable disease (G1M: 100%; G2M: 85%; G3M: 82%); partial response (G1M: 0%; G2M: 5%; G3M: 0%) and progressive disease (G1M: 0%; G2M: 10%; G3M:18%). The most common toxicities were hypertension (n = 19, 42.2%), proteinuria (n = 16, 35.6%), and fatigue (n = 14, 31.1%). Conclusion This study showed BEV is well tolerated and appears to be a promising systemic treatment option for patients with recurrent and refractory meningiomas.
Collapse
Affiliation(s)
- Priya Kumthekar
- The Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
- Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
- Northwestern University, Chicago, IL, USA
| | - Sean Aaron Grimm
- Department of Neurology, Rush University Medical Center, Chicago, IL, USA
| | - Roxanne T Aleman
- Department of Internal Medicine, Advocate Christ Medical Center, Oak Lawn, IL, USA
| | - Marc C Chamberlain
- University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, USA
| | - David Schiff
- University of Virginia School of Medicine, Charlottesville, VA, USA
| | - Patrick Y Wen
- Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard School of Medicine, Boston, MA, USA
| | | | - Demirkan Besim Gursel
- Northwestern University, Chicago, IL, USA
- Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
| | - David A Reardon
- Dana-Farber Cancer Institute, Boston, MA, USA
- Harvard School of Medicine, Boston, MA, USA
| | - Benjamin Purow
- University of Virginia School of Medicine, Charlottesville, VA, USA
| | - Masha Kocherginski
- Department of Preventative Medicine, Feinberg College of Medicine at Northwestern University, Chicago, IL, USA
| | - Irene Helenowski
- Department of Preventative Medicine, Feinberg College of Medicine at Northwestern University, Chicago, IL, USA
| | - Jeffrey J Raizer
- The Lou and Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
- Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
- Northwestern University, Chicago, IL, USA
| |
Collapse
|